Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ALICE B GOTTLIEB

Allopathic & Osteopathic Physicians Dermatology

NPI
1275581407
CMS profile
193500
Location
SOMERS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$93,799.05

181 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ALICE B GOTTLIEB

NPI 1275581407 · CMS profile ID 193500

Allopathic & Osteopathic Physicians / Dermatology

SOMERS, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1275581407?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ALICE B GOTTLIEB, NPI 1275581407, CMS profile ID 193500. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1275581407?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ALICE B GOTTLIEB, NPI 1275581407, CMS profile ID 193500. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1275581407?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ALICE B GOTTLIEB, NPI 1275581407, CMS profile ID 193500, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 4; records 101–150 of 181 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1275581407?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

181 matching records · $93,799.05 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 181 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–150 of 181.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $17.2706/06/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155577387 CMS
Janssen Biotech, Inc. $11.4506/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078470397 CMS
Janssen Biotech, Inc. $8.0906/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078470413 CMS
UCB, Inc. $8.8506/05/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155577385 CMS
Blueprint Medicines Corporation $34.4905/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147443991 CMS
Lilly USA, LLC $19.2305/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136023446 CMS
UCB, Inc. $116.0005/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087994 CMS
UCB, Inc. $19.6005/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087992 CMS
UCB, Inc. $5.3505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087986 CMS
UCB, Inc. $62.5005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087988 CMS
UCB, Inc. $62.5005/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087990 CMS
Incyte Corporation $101.6904/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141213544 CMS
ABBVIE INC. $28.4904/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824556 CMS
E.R. Squibb & Sons, L.L.C. $4,950.0004/26/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612672 CMS
ABBVIE INC. $18.2704/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824554 CMS
E.R. Squibb & Sons, L.L.C. $50.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612708 CMS
E.R. Squibb & Sons, L.L.C. $30.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612712 CMS
E.R. Squibb & Sons, L.L.C. $65.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612715 CMS
E.R. Squibb & Sons, L.L.C. $30.0004/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612719 CMS
E.R. Squibb & Sons, L.L.C. $543.2004/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612737 CMS
Dermavant Sciences, Inc. $25.5004/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127870772 CMS
UCB, Inc. $8.8004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087982 CMS
UCB, Inc. $11.5304/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087984 CMS
ABBVIE INC. $6.1104/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824552 CMS
Amgen Inc. $128.9504/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117264351 CMS
UCB, Inc. $95.4604/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087980 CMS
ABBVIE INC. $8.2404/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824550 CMS
Boehringer Ingelheim International GmbH $477.9303/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944219 CMS
Boehringer Ingelheim International GmbH $505.5503/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944221 CMS
Boehringer Ingelheim International GmbH $556.1003/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944225 CMS
Boehringer Ingelheim International GmbH $597.4103/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944227 CMS
Boehringer Ingelheim International GmbH $926.8303/31/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944239 CMS
Janssen Biotech, Inc. $17.0703/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078470405 CMS
Eli Lilly and Company $450.0003/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136015923 CMS
Eli Lilly and Company $450.0003/21/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136021582 CMS
UCB, Inc. $17.0703/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087978 CMS
ABBVIE INC. $13.4303/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824548 CMS
Dermavant Sciences, Inc. $14.7903/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1127870768 CMS
E.R. Squibb & Sons, L.L.C. $56.9503/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101612642 CMS
ABBVIE INC. $27.2903/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103824546 CMS
Janssen Scientific Affairs, LLC $38.8303/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078856350 CMS
Takeda Pharmaceuticals U.S.A., Inc. $91.2503/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137560469 CMS
Arcutis Biotherapeutics, Inc. $30.8603/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1121033630 CMS
Novartis Pharmaceuticals Corporation $30.6303/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086851605 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $44.2703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152122552 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $42.3703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152122554 CMS
UCB, Inc. $98.1703/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143087976 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $109.4503/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944195 CMS
Galderma Laboratories, L.P. $4,860.0003/07/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145300475 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $8.4802/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117944187 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $197,197.35 206
PY2020 $112,270.34 87
PY2021 $82,992.91 71
PY2022 $90,704.49 124
PY2023 $96,591.65 136
PY2024 $93,799.05 181
PY2025 $79,925.13 78

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $337,034.02 112
PY2024 Principal investigator $484,588.46 114
PY2023 Recipient $32,527.50 1
PY2023 Principal investigator $431,681.20 13
PY2022 Recipient $31,690.00 8
PY2022 Principal investigator $455,299.36 19
PY2021 Recipient $57,065.03 23
PY2021 Principal investigator $720,245.52 39
PY2020 Recipient $140,533.75 48
PY2020 Principal investigator $482,693.93 35
PY2019 Recipient $17,626.93 19
PY2019 Principal investigator $142,613.48 48

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

112 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $61.29 10/30/2025 Non-covered Recipient Entity
Ut Southwestern Medical Center
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PragmaTYK) No dispute reported 06/30/2026 1235992063
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249091
Principal investigator 1 Janssen Research & Development, LLC $254.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249835
Principal investigator 1 Janssen Research & Development, LLC $4,050.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249976
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250016
Principal investigator 1 Janssen Research & Development, LLC $425.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250038
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250358
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250817
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250832
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251453
Principal investigator 1 Janssen Research & Development, LLC $1,377.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251494
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251639
Principal investigator 1 Janssen Research & Development, LLC $270.00 06/11/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252651
Principal investigator 1 UCB SA $26,665.00 05/29/2025 Non-covered Recipient Entity
ICAHN INSTITUTE/GENETICS
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657806
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 05/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250009
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 05/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251906
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 05/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252375
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 05/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252871
Principal investigator 1 SANOFI US SERVICES INC. $31,157.50 05/27/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine Psychiatry
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226140754
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 04/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249215
Principal investigator 1 Janssen Research & Development, LLC $3,794.00 04/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250666
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 04/28/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251543
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $15,540.00 04/09/2025 Non-covered Recipient Entity
Mount Sinai School Of Medicine
A Study to Evaluate Effectiveness and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis No dispute reported 06/30/2026 1235995607
Principal investigator 2 UCB SA $1,050.00 03/28/2025 Non-covered Recipient Entity
ICAHN INSTITUTE/GENETICS
A Phase 3, open-label, parallel group, multicenter, extension study evaluating the long-term treatment of bimekizumab in study participants with moderate to severe hidradenitis suppurativa No dispute reported 06/30/2026 1246657718
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 03/25/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249883
Principal investigator 1 Janssen Research & Development, LLC $2,310.00 03/25/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249925
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 03/25/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250349
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 03/25/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250508
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249148
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249155
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249380
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249417
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249432
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249592
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249659
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249672
Principal investigator 1 Janssen Research & Development, LLC $10,384.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249740
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249761
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249776
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249805
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249845
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249860
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249875
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250076
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250330
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250389
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250483
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250514
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250564
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250610
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250633
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250674
Principal investigator 1 Janssen Research & Development, LLC $12,150.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250743
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250895
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250971
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251004
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251079
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251160
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251195
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251205
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251236
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251305
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251462
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251502
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251519
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251550
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251556
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251573
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251668
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251683
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251701
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251723
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251987
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252003
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252019
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252051
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252162
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252169
Principal investigator 1 Janssen Research & Development, LLC $1,320.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252192
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252245
Principal investigator 1 Janssen Research & Development, LLC $425.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252356
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252381
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252479
Principal investigator 1 Janssen Research & Development, LLC $254.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252605
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252613
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252620
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252636
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252682
Principal investigator 1 Janssen Research & Development, LLC $600.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252811
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252926
Principal investigator 1 Janssen Research & Development, LLC $205.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252949
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252996
Principal investigator 1 Janssen Research & Development, LLC $436.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175253019
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175253088
Principal investigator 1 Janssen Research & Development, LLC $1,516.00 03/12/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175253153
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249521
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175249569
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250297
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175250993
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175251426
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252423
Principal investigator 1 Janssen Research & Development, LLC $3,794.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252440
Principal investigator 1 Janssen Research & Development, LLC $4,589.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252893
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252935
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 02/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175253146
Principal investigator 1 UCB SA $829.14 02/20/2025 Non-covered Recipient Entity
ICAHN INSTITUTE/GENETICS
A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants with Active Psoriatic Arthritis. No dispute reported 06/30/2026 1246657704
Principal investigator 1 SANOFI US SERVICES INC. $31,157.50 02/18/2025 Non-covered Recipient Entity
Icahn School Of Medicine At Mount Sinai
A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa No dispute reported 06/30/2026 1226135802
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $56,160.00 02/03/2025 Non-covered Recipient Entity
Icahn School Of Medicine At Mount Sinai
A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Active Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE) No dispute reported 06/30/2026 1235996799
Principal investigator 1 Novartis Pharmaceuticals Corporation $210.00 02/01/2025 Non-covered Recipient Entity
ICAHN SCHOOL OF MED AT MOUNT SINAI
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S No dispute reported 06/30/2026 1190313093
Principal investigator 1 Janssen Research & Development, LLC $2,673.00 01/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252494
Principal investigator 1 Janssen Research & Development, LLC $1,678.00 01/27/2025 Non-covered Recipient Entity
Icahn Schl Of Medcn At Mount Sinai
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis (SPECTREM) No dispute reported 06/30/2026 1175252903
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $299.59 01/21/2025 Non-covered Recipient Entity
Icahn School Of Medicine At Mount Sinai-Department Of Dermatology
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment No dispute reported 06/30/2026 1235996775